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Aromatic amine acetylation has been recognized for many years as an important metabolic
polymorphism in humans because of its relationship to disease. This system serves as a model in
risk assessment because of its role in drug and carcinogen activation and detoxification and
because of the ease with which it is measured. However, possible interactions of NAT1-NAT2
phenotypes or genotypes illustrate the complexity of xenobiotic metabolism pathways.
Moreover, the use of such information for risk assessment is further complicated by the
association of the rapid phenotype with increased risk in colon cancer and the slow phenotype
with increased risk in urinary bladder cancer. Before this biomarker can be effectively utilized as a
significant predictor of individual risk, it will be necessary to identify specific sources of aromatic
amine exposure and to characterize further the substrate specificity of NAT1 and NAT2 in relation
to the multiplicity of enzyme variants occurring in human populations. Environ Health Perspect
105(Suppl 4):763-766 (1997)
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Definition of Marker
To be useful, a biomarker ofsusceptibility
must differentiate between the low- and
the high-riskgroups, have lowfalse positive
and low false negative rates, be easy to
perform, and be simple to interpret.
Acetyltransferases (NATI and NAT2, EC
2.3.1.5) meet these needs in many respects.
Since the recognition ofthe NAT2 acetyla-
tion polymorphism from its effects on iso-
niazide toxicity (1), it has been studied in
relation to several diseases in hope offind-
ing a useful marker ofsusceptibility. By the
use of different substrates, acetylation
activity could be separated into NAT1
(p-aminobenzoic acid[PABA]) and NAT2
(sulfamethazine [SMZ]) activity. Until
recent reports of variations in PABA
metabolism (2), NAT1 was thought to be
monomorphic while the polymorphism
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was ascribed to the NAT2 activity. The
identification ofthe genetic basis for the
phenotypic variations was identified in
1990 (3) for NAT2 and in 1993 (4) for
NATI. Other investigators quickly reported
the identification ofethnic variations (5)
when the most frequent variant alleles
seen in Caucasians differed in Asian and
African-American populations.
Investigators have found exposure
to xenobiotic plus NAT2 acetylation to
indicate risk for some diseases but not
others. The relationship between NAT2
acetylation phenotype and exposure to cer-
tain xenobiotics has been discussed by
Cartwright et al. (6). Slow phenotype sub-
jects who were exposed to compounds such
as aromatic amines had the greatest risk of
urinary bladder cancer. The use ofacetyla-
tion as a riskmarkerhas been evaluated in a
group oflung cancer cases and controls
with no difference identified between the
groups (7). Two groups working indepen-
dendy have reported a relationship between
rapid acetylation phenotype and risk of
development ofcolon cancer (8,9). Both
groups reported a 2- to 3-fold odds ratio for
colon cancer in the group that was rapid
acetylator phenotype. Increased risk of
colon cancer has also been associated with
the combination of rapid acetylator
(NAT2) and the rapid form ofCYP1A2 in
one report (10) and with the rapid acetyla-
tor genotype ofNATI (NATI*10) when it
occurred in association with the rapid
NAT2genotype (NAT2*4) (11) in another
report. A recent report found an increased
frequency of the rapid NAT2 genotype
(NAT2*4) with a specific breast cancer,
lobular carcinoma (12). Finally, Ambrosone
et al. report a greater than 5-fold increased
risk for premenopausal smokers who are
rapid acetylator phenotype and thin (13).
The impact ofacetylation phenotype in
these studies points out the need for infor-
mation on the tissue metabolism involved
in thecarcinogenicpathway.
Tissue distribution and substrate speci-
ficity help explain the epidemiology results
noted above. NATI and NAT2 occur in
the liver, with NAT2 being 2 to 10 times
the level of NAT1, depending on the
NAT2 status ofslow or rapid acetylator,
respectively. The predominant extrahepatic
form is NAT1, regardless ofthe acetylator
phenotype. NAT activityhas been found in
many extrahepatic tissues including colon
mucosa, placenta, and leukocytes (14-16).
NATI and NAT2 have a broad substrate
specificity (17,18) with catalytic activity for
arylamines, N-hydroxyarylamines and N-
hydroxy-N-acetylarylamines. However,
there is little activation ofthe foodborne
heterocyclic amines until these compounds
undergo N-oxidation by the polymorphic
cytochrome P4501A2. These data suggest,
and investigators found, that subjects at
greatest risk for a colon neoplasm from
exposure to heterocyclic amines in the diet
would be those individuals exposed at the
highest level who have the most efficient
metabolism ofthese compounds to proxi-
mate carcinogens (10). This model is also
compatible with the finding ofa role for an
NATI polymorphism in colon cancer risk
(11). Development ofsimilar understand-
ing in other malignancies awaits further
epidemiology and metabolism studies.
While acetylation can serve as a risk marker
for some diseases, the application ofthis
information will not be trivial.
Use ofAcetylation as a
Biomarker ofSusceptibility
Identification ofAt-RiskGroup
The primary advantage of a biomarker
such as metabolic phenotype is to allow
the identification of a group at risk for a
given disease. As mentioned in reference
to bladder and colon cancer, the power of
phenotype or genotype information is
improved when combined with exposure
data. Use of phenotype or genotype
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information to predict the at-risk group
also requires a biologically plausible mecha-
nism for the disease being studied.
Identification ofExposure Risk
Epidemiology is the tool used to identify
at-risk lifestyles. However, development of
a biologically plausible model requires
detailed metabolic studies of the liver as
well as of the tissues or organs at risk for
the disease of interest. Understanding the
mechanism of the risk may require the
investigator to use both susceptibility and
exposure biomarkers such as acetylation
phenotype and the presence of carcino-
gen-protein or carcinogen-DNA adducts.
Examples include adduct and metabolism
studies performed with liver, colon, and
bladder tissue, together with identification
ofhemoglobin and DNA adducts present
in cases and controls (17,19-23).
Armed with information about the
status of a genetic risk (acetylation status)
and the lifestyles that provide exposure
linked to the risk observed, one should be
better prepared to suggest behavioral
changes that may reduce the risk, e.g.,
avoidance ofheterocyclic amine exposures
bylimiting consumption ofmeat cooked at
high temperature. There may be better
individual adherence when recommenda-
tions are based on individual specific mea-
surement of genetic, environmental, and
dietary risk factors than has occurred with
the use ofgeneric warnings.
AdjustmentofTreatmentDosage to
MaximizeEffectand Minimize Risk
Acetylation phenotype has been studied
in the pediatric area to help determine
drug dosage ofa treatment regimen (24).
Where the substrate specificity is known
to involve the acetylation pathway, the
use ofmetabolic phenotyping or genotyp-
ing should provide more precise informa-
tion for determining effective therapeutic
dose for drugs undergoing acetylation.
The alternative is to monitor for toxicity
and to adjust the dose after toxicity is
diagnosed. The latter is commonly used
to adjust dosage for a wide range of
chemicals. Determining the functional
state of a given pathway has the obvious
advantage of allowing dosage adjustment
before toxicity develops.
StudyofEthnicGroup Relationships
Many of the ethnic variations in disease
incidence and mortality may have as a basis
differences in metabolic pathways as well as
differences in environmental and dietary
exposure. Investigators have reported a
wide range ofvalues for acetylation activity
in different groups (25-28).
Advantages and Limitations
ofAcetylation
Noninvasive, LowRisk
This susceptibility marker requires only a
urine sample if metabolic phenotyping is
performed. Ifgenotyping is used, a small
blood sample is usually taken and the indi-
vidual risk is usually regarded as minimal.
Phenotypingand
GenotypingMethods
Earlier phenotyping methods utilized
sulfamethazine, isoniazid, or dapsone as the
surrogate drug (8,29,30). Both blood and
urine samples were required. A rare but
severe allergic reaction can occur following
the administration ofsulfamethazine, and
isoniazid-induced hepatitis and polyneuritis
and dapsone neuropathy have also been
reported (31-33). Current phenotyping
involves administration of the surrogate
drug, caffeine, which has a much lower fre-
quency and severity ofadverse drug reac-
tion. Any adverse reaction to caffeine is rare
and requires a much higher dose than is
used (100 mg caffeine); most people who
are sensitive can be identified and exduded
by asking about sensitivity in advance of
administration. Sensitivity in our studies
has been < 1%, and no person has had an
adverse reaction to caffeine whether admin-
istered as coffee, a soft drink (Diet Coke) or
a NoDoz tablet (Table 1).
EnzymeExpression and
AmsyVariability
Expression ofthe enzyme activity over time
is an important factor. This permits sched-
uling ofthe study to be adjusted to accom-
modate the subjects' lifestyle. Day-to-day
Table 1. Acomparison of assay methods.
Surrogate Assay Sample Sample
drug method required Cost throughput Risk Status
Sulfamethazine HPLC Urine/blood Moderate Low Low Proven
Caffeine HPLC Urine Moderate to high Moderate Very low Proven
Caffeine ELISA Urine Low High Very low Unproven
variations in environmental and dietary
exposures have little impact on the acetyla-
tion activity (34). In addition, the caffeine
metabolites in the urine specimen collected
can be stabilized by acidification with
ascorbic acid and subsequent refrigeration.
CorrelatonbetweenPhenotype
andGenotype
Many (> 15) alleles of the NAT2 gene
have been identified in the human popu-
lation. Phenotyping can provide a simple
overview of activity level without the
necessity of checking for every possible
mutation that has been identified (35).
Discordance can indicate the possibility of
a yet unidentified genetic mutation (36)
or the possibility of interactions at the
gene or enzyme level.
At least two studies have reported
interactions between NATI and NAT2
activity that may complicate the use of
acetylation activity in risk assessment.
Through the use of phenotyping assays
with caffeine and PABA, Cribb et al.
found a correlation (r= 0.8, p= 0.0002)
between AFMU/1X and PABA activity in
subjects who were slow NAT2 (low
AFMU/1X ratio) (37). The second report
uses genotyping to demonstrate increased
risk ofcolon cancer when the rapid NATI
variant allele (NATi *10) occurs with the
rapid NAT2 (NAT2*4) allele (OR 2.8;
95% CI, 1.4-5.7;p= 0.003) (11), suggest-
ing a gene-gene interaction. The impor-
tance of the NAT] polymorphism is
further supported by a report of a dou-
bling of urinary bladder NATI activity
and of DNA adduct levels when the het-
erozygous genotype (NATi *1OINATi*4)
is compared to the homozygous genotype
(NATi*41NATi*4) (38). These studies
illustrate some ofthe difficulty encountered
in approaching risk assessment through the
measurement ofasingle polymorphism.
Ease ofDataAnalysis
While phenotyping produces a continuous
variable (with caffeine this is the urinary
molar ratio ofAAMU/1X or AFMU/1X),
most investigators find conversion of this
number to a dichotomous variable more
convenient. Plotting the data on a log-
probability scale gives a clear break between
rapid and slow phenotype that can be used
to assign slow or rapidphenotype (34).
Cost
The phenotyping assay requires measure-
ment of the metabolites of a surrogate
drug, caffeine. This information comes
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from a high-pressure liquid chromatogra-
phy (HPLC) assay performed on a sample
ofurine collected after caffeine dosing. The
use of an HPLC system that includes a
diode array detector is important to assure
correct peak assignment. This equipment is
expensive ($40,000 U.S.) and the system is
not trivial to maintain.
The reverse-phase columns used in the
assay seem to have a significant variation
in their performance level. Because ofthis
variation, columns should be purchased
from the same lot number if at all possi-
ble. Even in the same lot, some columns
give poor separation of caffeine metabo-
lites and cannot be used, further adding
to the expense.
Sample preparation requires extraction
steps that are expensive in personnel time.
This cost is reduced somewhat by batch
processing offrozen, stored samples. The
low throughput ofthe system (20-40 sam-
ples/24 hr) is costly in the amount ofoper-
ator time required to produce a given
result. This limit has been approached
by trying to shorten the time per chro-
matogram (solvent gradient programs at
about 45 min) by varying column and gra-
dient conditions. Moreover, the newer,
computerized systems have markedly
improved the analysis ofthe chromatogram
by automating the identification of the
peaks and by automating the calculation of
values from standard curves.
Approximately 5% of the urine sam-
ples have interfering substances that
require reanalysis of the sample. Efforts
to identify these substances have been
unsuccessful to date.
For the ratio ofAFMU/1X to reflect
NAT2, the sample is usually collected for 1
hr from the fourth to the fifth hour after
caffeine dosing. No other caffeine is permit-
ted between dosing and sample collection.
Food and liquids are permitted to allow
adequate urine volume to prevent interfer-
ence with the excretion ofmetabolites and
therefore the phenotyping assay.
Conclusions
Because of the large number of mutations
identified in the NAT2 gene, the use of
phenotype is still an important technique.
Phenotype gives the investigator a simpler
classification system (rapid vs slow) than is
easily achieved with a system of 15 or more
alleles combined in many possible ways.
The ability of NAT2 phenotype to predict
risk has been shown in colon cancer and in
bladder cancer (6,8,10,39-43). Failure to
identify an association with other diseases
may be due to a lack ofunderstanding of
the mechanism of the disease and its link
to NAT2. This could result because there
is no link or because the link is more com-
plex than the investigator recognizes. One
example of the latter is provided by the
identification of meat cooking, CYP1A2,
and NAT2 as risk factors for development
ofcolon neoplasia (10). The interaction of
NATI and NAT2 is another important
example (11,37).
A method that is less expensive and has
more rapid sample throughput would be
very desirable (Table 1). A recent report
details a rapid, low-cost, enzyme-linked
immunosorbent assay (ELISA) for use in
phenotyping for NAT2 (44) and studies
are underway to compare this method with
HPLC and with genotyping.
Recommendations
Phenotyping should be continued along
with specific genotyping as we gain experi-
ence with larger numbers, better assay meth-
ods, and the interpretation ofmore complex
relationships among the enzymes involved
in xenobiotic metabolism. The current
understanding ofxenobiotic metabolism,
the measurement ofthat metabolism, and
the evaluation ofexposure are all still rela-
tively incomplete. Therefore, the use ofthis
information to assign specific individual
risk, while desirable, has not yet been vali-
dated in a cohort- or population-based
study. The next step will be to use this
information as an intervention tool to
reduce risk byreducing exposure to environ-
mental and dietary factors proposed to be
linked to a disease. The effect of these
actions must then be evaluated to determine
whether or not at-risk behavior change
occurs and whether or not risk reduction
can be implemented.
Acetylation continues to be an interest-
ing metabolic step because it is easily and
safely measured, and it seems to play an acti-
vation role in colon cancer and a detoxifica-
tion role in bladder cancer. This system is
likewise important in drug toxicity as well as
in other chronic diseases. Finally, there are
well recognized interindividual variations
that may explain some ofthe known disease
variability among different ethnic groups.
All ofthese areas need further exploration
before wewill be able to prescribe individual
specific prevention strategies.
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